Pure red cell aplasia with antierythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another

Current Medical Research and Opinion

Volumn 20, Issue 1, 2004, Pages 83-86

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Epidemiology; Erythropoietin, recombinant; Injections, subcutaneous; Kidney failure

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANTIBODY DETECTION; ANTIBODY PRODUCING CELL; CALCULATION; CHRONIC KIDNEY FAILURE; DATA BASE; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PURE RED CELL ANEMIA; REVIEW;

EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; RED-CELL APLASIA, PURE;

EID: 0346058050     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002702     Document Type: Review

References (13)

1. Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75
2. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red cell aplasia and recombinant erythropoietin. Letter to the Editor. N Engl J Med 2002;346:1584-5
3. Montagnac R, Boffa GA, Schilinger F, Guillaumie J. Sensibilisation à l'erythropoétine humaine recomninante chez une hémodialysée. Presse Med 1992;21:84-5
4. Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M. A case of anti-erythropoietin antibodies following recombinant human erythropoietin treatment. In: Erythropoietin: Molecular Physiology and Clinical Application. New York: Marcel Dekker, 1993:266-75
5. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies to recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996;335:523-4
6. Prabhakar SS, Muhlfelder T Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997;47:331-5
7. Hoffbrand AV, Lasch HG, Nathan DG, Thompson RB, Waller HD, Weatherall DJ, eds. Haematological effects of drug therapy. Clin Haematol 1980;9:455-691
8. UK Medicines Control Agency. Eprex (epoetin alfa)and pure red cell aplasia - contraindication of subcutaneous administration to patients with chronic renal disease. http://medicines.mhra.gov.uk/ ourwork/monitorsafequalmed/ safetymessages/eprex121202.pdf (accessed 24 September 2003)
9. Agence Française de Sécurité Sanitaire des Produits de Santé. Website Letter from Janssen-Cilag to French Healthcare Professionals of July 19th 2002. (accessed 24 September 2003)
10. Health Canada. Important Drug Safety Update. http://www.hcsc.gc.ca/hpfb-dgpsa/tpd-dpt/eprex_e.html (accessed 6 August 2002)
11. Johnson & Johnson Website posting of July 14th 2003. http://www.jnj.com/news/jnj_news/1021024_095632.htm (accessed 15 July 2003)
12. Bader FG. Immunogenicity of erythropoietin in the context of biosimilar products. Presented at Scientific Considerations for Comparability of Biopharmaceuticals, Special Meeting in Conjunction with the 2003 PDA International Congress, Courses and Exhibition, 27-28 February 2003, Prague, Czech Republic
13. US Renal Data System, USRDS 2001 Annual Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes, and Digestive and Kidney Diseases, Bethesda, MD, 2001